Edward M. Tavel, Jr. M.D.

Pain Specialists of Charleston
Clinical Trials of South Carolina
2695 Elms Plantation Blvd – Suite A and Suite D
Charleston, SC 29406

Clinic: 843-818-1181 ◆ Research: 843-725-5067 ◆ Fax: 843-818-1145

Education

1981-1985	Davidson College, Davidson, NC Bachelor of Science, Pre-Med
1985-1989	Medical University of South Carolina, Charleston, SC MD

Residency

1989 – 1990	Internship Roanoke Memorial Hospital, Roanoke VA
1990 - 1993	Anesthesiology University of North Carolina, Chapel Hill, NC (Residency)
1992 - 1993	University of North Carolina, Chapel Hill, NC (Chief Resident)

Professional Experience

Pain Specialists of Charleston, PA,
Owner/Medical Director 2009 – Present

Pain Care Physicians of Charleston
Managing Partner, 2006-2009

Medical Executive Committee
Trident Regional Medical Center, 2005-2009

Palmetto Anesthesia of Charleston
Managing Partner, 2003-2009

Trident Anesthesia Group
Member: 1993-2009, Partner: 1996-2009, Managing Partner: 2003-2009

Relevant Affiliations

The Academy of Pharmaceutical Physicians and Investigators (**APPI**), 2010 – Present

Society of Clinical Research Associates (**SOCRA**), 2010 – Present

Drug Information Association (**DIA**), 2010 – Present

Atlanta Center for Clinical Research, Corp., 2008 - Present

International Spinal Intervention Society (ISIS), 2006-Present

American Society of Interventional Pain Management, 2006-Present

American Society of Regional Anesthesia

Licensures and Certifications

South Carolina Board of Medical Examiners, 1993 - Present

Board Certified in Anesthesiology, 1994 – Present

Board Certified in Pain Management, 2009 - Present

Posters and Publications

Tavel, E., K. Slavin, K. Amirdelfan, T. Yearwood, C. Kim, G. Phillips, J. Pope, C. McLeod, A. Fabi, T. Houden, R. Justiz, P. Staats, R. North, S. Falowski, D. Wilson, B. Edmiston, A. Taghva, D. Paicius, T. Deer
Understanding Bust Stimulation: Insights into Mechanism of Action and Programming Optimization from the SUNBURST Study

Tavel, E., Rosenberg, J., Jackson, A., Ghodsi, A., Saranita, J., Davis, M.
Comparison of SCS Treatment With and Without Prior Surgery. Poster – to be presented at World Institute of Pain (WIP) Congress; 2014 May 7-10;
Maastricht, Netherlands

Tavel, E. Dunteman, D. Sweeney, M.
Safety and Efficacy of Gastroretentive Gabapentin in Real-World Clinical Practice for Treatment of Patients with Postherpetic Neuralgia (PHN). Poster session presented at: The American Academy of Pain Medicine's 29th Annual Conference; 2013 April 9-14;
Ft. Lauderdale, Florida

Tavel, E. Brownlow, C. Howes, G. Haley, T. Creamer, M. Ghodsi, A. Rosenberg, J. Washburn, S.
The validation of a multi sensor on-body monitoring system to objectively measure changes in physical function and sleep, in patients undergoing a spinal cord stimulation trial; Interim results. Poster session presented at: From Innovation to Reality. 16th Annual North American Neuromodulation Society; 2012 December 6-9; Las Vegas Nevada

Research-Specific Training

DIA Annual Conference – June 2011

Good Clinical Practice Training – 2015

SOCRA Annual Conference – 2010 Course Series 10001

NIH Online Training in the Protection of Human Research Subjects – 2008, 2010 cert # 542183

CITI Course for Human Subjects Research – 2015

Clinical Research Experience

- "A Randomized Withdrawal, Double blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy, Tolerability, and Safety of XXXX, in Patients with Moderate to Severe Chronic Low Back Pain" November 2015-Present
  Principal Investigator
  First Patient to Screen & Randomize Nationwide

- "A Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of XXXX for the Treatment of Chronic Pain caused by Osteoarthritis of the Knee: A Proof of Concept Study" November 2015-Present
  Principal Investigator

- " A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topical Applied XXXX in Patients with Postherpetic Neuralgia" November 2015-Present
  Principal Investigator

- "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of XXXX in Patients with Episodic Migraine" November 2015- Present
  Sub-Investigator

- "A Phase 3, Randomized, Double Blind, Placebo-Controlled Study of XXXX in Patients with Chronic Migraine" November 2015-Present
  Sub Investigator

- "A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate The Efficacy and Safety of an Intra-Articular Injection of XXXX in Adults With Pain Due to Osteoarthritis of the Knee"
  October 2015-January 2016
  Principal Investigator

- "Long-term, Prospective, Multinational, Parallel-cohort Study Monitoring Safety in Patients with MS Newly Started on XXXX Once Daily or Treated with Another Approved Disease-modifying Therapy." September 2015-Present
  Sub-Investigator

- "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of XXXX in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy" May 2015-Present
  Sub- Investigator

- "A phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of XXXX as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn's Disease" May 2015- Present
  Sub- Investigator

- "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of XXXX in Patients with Episodic Cluster Headaches" February 2015-Present
  Sub- Investigator

- "A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of XXXX Alone or Combined XXXX in Subjects with Chronic Discogenic Lumbar Back Pain Through 12 Months" February 2015-Present
  Principal Investigator

- "Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of XXXX Compared with XXXX and Placebo in Patients with Moderate to Severe Ulcertive Colitis Who Are Naïve to TNF Inhibitors" January 2015-Present
  Sub- Investigator

- "A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of XXXX for the Treatment of Opioid-induced Constipation in Subjects with Nonmalignant Chronic Pain Receiving Opioid Therapy" October 2014 – 2015
  Principal Investigator
  Two Screens On The Day Of Site Activation

- "A Phase 3 Multi-Center Actual-Use Study on the Safety of XXXX for the Treatment of Moderate to Severe Acute Pain Associated with Osteoarthritis of the Knee or Hip" September 2014-2015
  Principal Investigator
  Two Screens On The Day of Site Activation

- "A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of XXXX Administered Orally for 8 Weeks to Adult Outpatients with Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain" September 2014 - 2015
  Principal Investigator
  Two Screens On The Day Of Site Activation

- "A Phase 2, Randomized, Double-Blind, Placebo and Active-Controlled Trial of XXXX In Patients with Mild to Moderate Osteoarthritis Pain of the Knee" June 2014 – July 2015
  Principal Investigator
  Number One Site for Enrollment
  Two Screens On The Day Of Site Activation

- "An interventional Phase II/III randomized, double-blind trial investigating the efficacy and safety of intravenous XXXX in subjects with complex regional pain syndrome type I (CRPS-I)" August 2014-Present
  Principal Investigator
  Top 3 for Enrollment

- "A Phase 3 Multicenter, Randomized, Double-blind, Controlled, Comparative Study of XXXX in Patients with Lumbar Disc Herniation" January 2014-Present
  Principal Investigator
  Top Five Site for Randomization

- "A Prospective, Randomized, Multi-Center, Controlled Clinical Trial to Assess the Safety and Efficacy of the XXXX System in the Treatment of Chronic Pain." January 2014-Present
  Principal Investigator
  Recognized as Second Highest Enroller in Study Nationwide

- "A Phase 2b Randomized, Double-Blind, Vehicle-Controlled, Repeat-Dose, Multi-Center, Efficacy and Safety Clinical Trial of XXXX in Subjects with Moderate to Severe Pain associated with Osteoarthritis of the Knee following Cessation of Pain Therapy." December 2013-2014
  Principal Investigator

- "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Compared to Placebo as Add-on to Preexisting Antihyperglycemic Therapy over 16 Weeks with 36-week Extension in Type 2 Diabetic Subjects with Chronic Kidney Disease Stage 4 or Stage 5 on Dialysis" December 2013-2014
  Principal Investigator

- "A Randomized, Prospective, Multicenter, Clinical Study Designed to Demonstrate the Safety and Efficacy of the XXXX Therapy to Manage Patients with Chronic Intractable Pain" November 2013-2015
  Principal Investigator
  Recognized as second highest enroller in study nationwide
  Recognized for highest randomizations nationwide

- "A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of XXXX in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy," September 2013-2015
  Principal Investigator

- "A Phase 3b, Randomized, Double-Blind, Placebo controlled, Parallel-Treatment Group, Multicenter Efficacy And Safety Study Of XXXX In Subjects With Anal Fissure," May 2013 – March 2014 Principal Investigator
- "Cardiovascular Safety & Renal Microvascular Outcome with XXXX in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk," April 2013 – Present Principal Investigator

- "A Phase 3, Open-Label, Long-Term Study to Evaluate the Safety, Tolerability and Analgesic Efficacy of XXXX in Subjects with Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time," January 2013 – July 2013 Principal Investigator

- "A Phase 2, A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of a Single Treatment of XXXX in Patients With Postherpetic Neuralgia," January 2013 – 2014
  Principal Investigator

- "A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of XXXX in Patients with Post-Herpetic Neuralgia (PHN)," January 2013 – 2015
  Principal Investigator

- "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-term Safety and Tolerability of XXXX for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain," January 2013 –2014
  Principal Investigator

- "A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXXX to Assess the Analgesic Efficacy and the Management of Opioid-induced Constipation in Opioid-experienced Subjects with Controlled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy," October 2012-September 2013
  Principal Investigator

- "A Multicenter, 12-Week, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of XXXX In Subjects With Moderate To Severe Chronic Low Back Pain"," June 2012- June 2012- April 2014
  Principal Investigator

- "A Phase 3 , Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of XXXX Versus Placebo in Opioid-Experienced and Opioid-Naïve Subjects with Moderate-to-Severe Chronis Low Bank Pain," August 2012 - August 2014
  Principal Investigator
  Finished 8th out of 49 sites

- "A Phase 3, Open Label Safety Study of XXXX in Subjects with Osteoarthritis or Chronic Low Back Pain," May 2012 - May 2012 – July 2013
  Principal Investigator

- "A Phase 2 Enriched Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability and Safety of XXXX in Opioid-Naïve Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee," June 2012 – October 2013
  Principal Investigator
  Recognized for first place titration and randomization of study subjects Recognized as second highest screening study-wide

- "An Open-Label 52-week Study to Assess the Long-Term Safety of XXXX in Patients with Opioid-Induced Constipation," May 2011- January 2013
  Principal Investigator
  Recognized for exceptional strategies in identifying, pre-screening and screening patients
  Recognized as high enroller 1st month of enrollment Recognized for highest enroller in our region

- "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study with an Open-label Run to Assess the Efficacy and Safety of XXXX in Subjects with Moderate to Severe Chronic Low Back Pain," 2011-2012
  Principal Investigator
  Recognized as high enroller

- "A Phase 4, Open Label, Study of Safety and Effectiveness of XXXX Tablets in the Treatment of Patients with Post-herpetic Neuralgia in Clinical Practice," 2011-2012

Principal Investigator
Enrollment goal reached in 10 days Highest enroller overall to date

- A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXXX in Subjects With Opioid-Induced Constipation," December 2011-2012
  Principal Investigator
  Recognized as top three in screening and enrollment in the United States

- "A Multi-Centered Evaluation of Patients with Chronic Pain of the Trunk and/or Limbs using Paddle Lead(s). November 2011 - Present
  Principal Investigator
  Recognized as top enrollers nationwide (combined Q1 and Q2 in 2012) Reached sponsor enrollment goal within 4 months Enrollment goal doubled by sponsor

- "A Multi-Centered Evaluation of Patients with Chronic Pain of the Trunk and/or Links using Paddle Lead(s); Validation of a Multi-Sensor On-Body Monitoring System to Objectively Measure Changes in Physical Function and Sleep in Patients Undergoing XXXX," June 2012 – July 2016
  Principal Investigator
  Selected for sub-trial based on stellar performance, outcomes and data within primary study

- "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)" 2010-2012 Principal Investigator

- "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)" 2011-December 2012
  Principal Investigator

- "An Evaluation of the Burden of Illness among Adults in the United States with Peripheral and Central Neuropathic Pain", Oct. 2011
  Principal Investigator
  Enrollment goal reached within 3 weeks Tripled enrollment goal set by sponsor

- "A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of XXXX in Subjects with Opioid-Induced Bowel Dysfunction", 2010-2011
  Principal Investigator
  Recognized as high enroller

- "A Multicenter, Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Three Non-Steroidal Medications" 2010-Dec. 2015
  Principal Investigator
  Recognized as High Enroller - Second Highest Enroller WORLD WIDE
  Recognized as Having High Level of Subject Retention

- "A Multi-center, Randomized, Double-blind, Placebo-controlled Study an Open-label Run-in to Assess the Efficacy, Tolerability, and Safety XXXX or XXXX Compared to Placebo in Opioid-Naïve Subjects with Moderate to Severe Chronic Pain due to Osteoarthritis of the Knee" 2008-2009

Principal Investigator